Rhythm Pharmaceuticals, Inc.RYTMNASDAQ
LOADING
|||
R&D Expense Growth Accelerating
Trending higher, above historical average, modest growth trend.
Left:
||||
Year-over-year research & development expense growth
Latest
76.33%
↑ 35% above average
Average (9y)
56.63%
Historical baseline
Range
High:174.12%
Low:-17.36%
CAGR
+8.9%
Consistent expansion
| Period | Value |
|---|---|
| 2024 | 76.33% |
| 2023 | 24.23% |
| 2022 | 4.32% |
| 2021 | 15.12% |
| 2020 | -17.36% |
| 2019 | 117.43% |
| 2018 | 119.87% |
| 2017 | 16.84% |
| 2016 | 174.12% |
| 2015 | 35.38% |